Yi Lin, MD, PhD, discussess updated results of the phase 1 CRB-401 study in relapsed/refractory multiple myeloma.
Yi Lin, MD, PhD, consultant, Division of Hematology, Department of Internal Medicine, consultant, Division of Experimental Pathology and Laboratory Medicine, Department of Laboratory Medicine and Pathology, assistant professor of medicine and oncology, Mayo Clinic, discusses updated results of the phase 1 CRB-401 study (NCT02658929) in relapsed/refractory multiple myeloma.
Updated results from the phase 1 CRB-401 study, which were presented virtually during the 2020 ASH Annual Meeting & Exposition, showed that 27.4% of patients evaluated had high-risk cytogenetics and 37.1% had extramedullary disease. Notably, 51.6% of these patients required bridging therapy during manufacturing of CAR T cells. Patients were heavily pretreated, having received a median of 6 prior lines of therapy. About 70% of patients were triple-class refractory or refractory to their most recent prior therapy, Lin says.
Overall, the patients tolerated idecabtagene vicleucel (ide-cel; bb2121) well. As patients also received lymphodepletion chemotherapy, low blood count was a common adverse effect. However, this toxicity is typically resolved within the first 3 months following the infusion of CAR T-cell therapy, Lin concludes.